National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China.
Molecules. 2020 Mar 19;25(6):1409. doi: 10.3390/molecules25061409.
Coxsackievirus B3 (CVB3) is the most common cause of acute and chronic viral myocarditis, primarily in children, while human adenovirus infections represent a significant cause of morbidity and mortality worldwide, in people of all ages. A series of novel 2-benzoxyl-phenylpyridine derivatives were evaluated for their potential antiviral activities against CVB3 and adenovirus type 7 (ADV7). Preliminary assays indicated that some of these compounds exhibited excellent antiviral effects on both CVB3 and ADV7 viruses; they could effectively inhibit virus-induced cytopathic effects, reduce viral progeny yields, and had similar or superior antiviral activities compared with the control drug, ribavirin. Further, these compounds targeted the early stages of CVB3 replication in cells, including viral RNA replication and protein synthesis, rather than inactivating the virus directly, inhibiting virus adsorption/entry, or affecting viral release from cells. Our data demonstrate that the tested 2-benzoxyl-phenylpyridine derivatives are effective inhibitors of CVB3 and ADV7, raising the possibility that these compounds might be feasible candidates for anti-viral agents.
柯萨奇病毒 B3（CVB3）是导致急性和慢性病毒性心肌炎的最常见原因，主要发生在儿童中，而人类腺病毒感染是全世界各年龄段人群发病率和死亡率的重要原因。一系列新型 2-苯并恶唑基-苯基吡啶衍生物被评估了其对 CVB3 和腺病毒 7 型（ADV7）的潜在抗病毒活性。初步研究表明，其中一些化合物对 CVB3 和 ADV7 病毒均表现出优异的抗病毒作用；它们可以有效抑制病毒引起的细胞病变效应，减少病毒后代产量，与对照药物利巴韦林相比具有相似或更优的抗病毒活性。此外，这些化合物针对 CVB3 在细胞内的早期复制阶段，包括病毒 RNA 复制和蛋白质合成，而不是直接使病毒失活，抑制病毒吸附/进入，或影响病毒从细胞中的释放。我们的数据表明，所测试的 2-苯并恶唑基-苯基吡啶衍生物是 CVB3 和 ADV7 的有效抑制剂，这提示这些化合物可能是有前途的抗病毒药物候选物。
